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Identity 
Other names: AIGF; FGF-8; HBGF-8; KAL6; 
MGC149376 




Figure 1. Exon representation of FGF8 isoforms (modified from 
Gemel et al., 1996). 
Transcription 
Alternative splicing of FGF8 gene gives rise to eight 
potential protein isoforms in the mouse (FGF8a-h) and




Fibroblast growth factor 8 is a secreted protein mitogen 
which belongs to fibroblast growth factor family. It 
exerts its action by binding cell surface tyrosine kinase 
recetors FGFR1-4 (Powers et al., 2000; Sleeman et al., 
2001). It is implicated in embryonic development, 
tumor growth and angiogenesis. FGF8 was originally 
found as an androgen-induced growth factor (AIGF) 
from the conditioned medium of the androgen-
dependent mouse mammary carcinoma cell line SC-3 
(Tanaka et al., 1992). Whether its expression is directly 
androgen regulated is not clear (Gnanapragasam et al., 
2002; Erdeich-Epstein et al., 2005). However, it has 
been shown to be co-expressed with androgen receptor 
in breast and prostate cancer. FGF8 is also called Kal-6 
since it belongs to genes which have been shown to be 
mutated in a subset of patients with Kallman's 
syndrome (combination of hypogonadotropic 
hypogonadism and anosmia). In addition, FGF8 
belongs to growth factors that could be isolated by 
affinity chromatography on Heparin-Sepharose 
columns and are thus called heparin-binding growth 
factors (HBGF). The interaction of heparin with FGF 
stabilizes FGF to denaturation (Gospodarowicz and 
Cheng, 1986) and proteolysis and is required for FGF 
mediated FGFR activation (Ornitz, 2000). 
Expression 
In the adult human, FGF8 is expressed in kidney, testis, 
prostate, breast, peripheral blood leukocytes and in 
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bone marrow (Ghosh et al., 1996; Marsh et al., 1999; 
Tanaka et al., 1998). However, during embryonal 
development, its expression is more widely distribued. 
The expression pattern of FGF8 during mouse 
embryonal development suggested roles for FGF8 in 
the morphogenesis of limbs, central nervous system 
and face, pharyngeal and cardiac systems, and the 
urogenital organs (Ohuchi et al., 1994; Heikinheimo et 
al., 1994; Crossley et al., 1996a; Crossley et al., 1996b; 
Haraguchi et al., 2000). Importantly, FGF8 expression 
is essential in gastrulation since homozygous loss of 
FGF8 leads to early embryonic lethality (Sun et al.,
1999). 
Of the cancer cell lines, FGF8 expression has been 
detected in LNCaP, DU145, ALVA-31 and PC-3 
prostate cancer cell lines, in MCF-7, ZR-75-1, T47-D, 
MDA-MB-231, SKBR-1, BT-549 and Hs578T breast 
cancer cell lines (Tanaka et al., 1995; Ghosh et al., 
1996; Johnson et al., 1998; Marsh et al., 1999) and in 
UT-OV-2, UT-OV-4, UT-OV-5, UT-OV-6, UT-OV-
10, UT-OV-11 and SK-OV-3 ovarian cancer cell lines 
(Valve et al., 2000). FGF8 has been shown to be 
expressed in benign breast and prostate lesions and in 
breast and prostate cancer (Leung et al., 1996; Tanaka 
et al., 1998; Dorkin et al., 1999). FGF8 expression is 
correlated with the expression of androgen receptor in 
both breast and prostate cancer (Wang et al., 1999; 
Tanaka et al., 2002). In prostate cancer the expression 
of FGF8 correlates with the poor prognosis (Dorkin et 
al., 1999). FGF8b is the primary isoform detected in 
breast cancer (Marsh et al., 1999) but in prostate c ncer 
in addition to FGF8b, also FGF8a and FGF8e have 
been detected (Valve et al., 2001). Ovarian cancers of 
wide variety of histological types express FGF8 andits 
receptors and increased staining intensity of FGF8 has 
been associated with loss of differentiation within the 
tumors (Valve et al., 2000). 
Function 
FGF receptors, to which FGF8 binds, are 
transmembrane proteins containing three extracellular 
immunoglobulin-like domains (IgI, IgII, IgIII), an 
acidic region between IgI and IgII, a transmembrane 
domain, and an intracellular tyrosine kinase domain. 
The involvement of receptor tyrosine phosphorylation 
in FGF signalling was first suggested by early binding 
studies (Moscatelli et al., 1987). An important 
mechanism by which FGF receptors determine 
specificity for different FGFs is by alternate exon usage 
of the IgIII forms. The exons coding for the three 
possible IgIII domains (IgIIIa, IgIIIb, IgIIIc) are 
situated contiguously and in the same order in FGFR1,  
FGFR2 and FGFR3 (Johnson et al., 1991; Chellaiah et 
al., 1994). The FGFR4 gene is unique in that there is 
only one possible form of its IgIII domain (Vainikka et 
al., 1992). IgIIIa splice variant codes for a secreted 
truncated protein which is not capable of transducing 
signals but instead may act to sequester released FGFs 
and potentially inhibit FGF signaling. FGF8 
predominantly activates c-spliceforms of the receptors 
which are expressed mainly by the cells of 
mesenchymal origin. Thus, epithelially secreted FGF8 
signals to neighbouring mesenchyme and may have a 
role in the epithelial-mesenchymal transition important 
in carcinogenesis. However, FGF8 is also well known 
as an autocrine growth factor in the stimulation of 
cancer cell proliferation, anchorage independent growth 
and migration (Figure 2). Full FGF receptor activation 
requires a coreceptor, a cell surface heparan sulfate 
proteoglycan (HSPG), which traps the growth factor on 
the cell surface and stabilizes the FGF/FGFR complex 
(Ornitz, 2000). Tissue-specific heparan fragments ad
tissue specific sulfation patterns of heparans may 
regulate FGFs by controlling their diffusion in the 
extracellular matrix and their ability to activate specific 
receptors (Chang et al., 2000). Strong binding of FGFs 
to heparin and heparan sulfated proteoglycans leads to 
deposition and sequestration of secreted or exocytosed 
FGFs in the extracellular matrix. Storage of FGFs in 
the extracellular matrix may serve as an angiogenesis 
regulatory reservoir released in response to degradation 
of the matrix (Folkman et al., 1988). 
FGF activation of FGFRs results in activation of 
signalling cascades such as phospholipase C gamma, 
phosphatidiylinositol-3 kinase and MAPK pathways 
that lead to expression of target genes and increased 
cell proliferation, survival and migration. Negative 
modulators of FGF signalling that have been found to 
be co-expressed with FGF8 include sprouty proteins 
(Spry1, Spry2), MAP-kinase phosphatase 3 (Mkp3) and 
Sef (Similar expression to FGFs) genes. Recently, 
FGF8 has been shown to downregulate the expression 
of thrombospondin-1 (TSP-1) (Mattila et al., 2006) 
through two independent pathways, MEK1/MEK2 and 
PI3K (Tarkkonen et al., 2010). Repression of TSP-1 
may be an important mechanism involved in the 
induction of an angiogenic phenotype and growth of 
FGF8-expressing cancer. 
Homology 
FGF8 has 70-80% amino acid sequence identity with 
FGF17 and FGF18. FGF8, FGF17 and FGF18 form 
FGF8 subfamily which has similar receptor binding 
properties and some overlapping sites of expression 
(Maruoka et al., 1998). 
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Figure 2. Schematic view of the effects of FGF8 on tumor growth and progression. Morphological change in S115 breast cancer 
cells in vitro (up), induction of angiogenesis in nude mouse S115 tumors (middle, immunohistochemical staining for CD34), increase in 




Loss-of-function mutations of FGF8 are associated 
with isolated hypogonadotropic hypogonadism with 
variable sense of smell (Kallmann syndrome), cleft 
lip/palate, deafness and flat nasal bridge camplodactyly 
and hyperlaxity in the human (Trarbach et al., 2010). 
Implicated in 
Breast and prostate cancers 
Disease 
In humans FGF8 has been shown to be expressed in 
benign breast and prostate lesions and in breast and 
prostate cancer (Tanaka et al., 1998; Leung et al., 1996; 
Dorkin et al., 1999). Furthermore, it has been detect d 
in bone metastases of prostate cancer (Valta et al., 
2008). The expression of FGF8 has been shown to be 
increased in breast cancer when compared to non-
malignant breast tissue (Marsh et al., 1999). FGF8 
expression is correlated with the expression of 
androgen receptor in both breast and prostate cancer 
(Tanaka et al., 2002; Wang et al., 1999). 
Prognosis 
In prostate cancer the expression of FGF8 correlates 
with the poor prognosis (Dorkin et al., 1999). FGF8b is 
the primary isoform detected in breast cancer (Marsh et 
al., 1999) but in prostate cancer in addition to FGF8b, 
also FGF8a and FGF8e have been detected (Valve et 
al., 2001). Interestingly, both FGF8 isoforms a and e 
are expressed more commonly in prostate cancer than 
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in benign prostate samples used as controls (Valve et 
al., 2001). Surprisingly, FGF8b, despite of being the 
most transforming isoform (Ghosh et al., 1996) is 
expressed in a similar manner in both benign and 
malignant prostate samples (Valve et al., 2001). The
clinical data and experimental evidence strongly 
suggest that FGF8 has a role in the promotion of 
growth and progression of hormonal cancers. FGF8 has 
been shown to function as a potent autocrine growth 
factor in the stimulation of proliferation of breast and 
prostate cancer cells. In addition, its paracrine eff cts in 
terms of induction of angiogenesis and osteoblastic 
differentiation may contribute to tumor progression. 
Oncogenesis 
When transfected to NIH-3T3 cells FGF8 induces 
anchorage independent growth of the cells and 
tumorigenesis in nude mice (Kouhara et al., 1994). 
MMTV-Fgf8 transgenic mice develop mammary and 
salivary gland neoplasia and ovarian stromal 
hyperplasia (Daphna-Iken et al., 1998). Targeted 
expression of FGF8 in transgenic mouse prostate has 
been shown to result in prostatic intraepithelial 
neoplasia, stromal hyperplasia and increased 
inflammation (Song et al., 2002; Elo et al., 2010). 
Several breast and prostate cancer cell lines transfected 
with FGF8 have been shown to exhibit increased 
growth properties. Also morphology and motility of the 
cells are reportedly altered in response to FGF8 
overexpression (Mattila et al., 2001; Ruohola et al.,
2001) indicating that FGF8 may affect cytoskeletal and 
adhesion molecule expression of cancer cells. Similar 
to FGF2, FGF8 has been shown to have angiogenic 
potential (Mattila et al., 2001). Increased FGF8 
expression is associated with rich vasculature of fast
growing tumors (Valta et al., 2008; Valta et al., 2009; 
Tuomela et al., 2010). As FGF8 has a central role in 
hormonal cancers which preferentially metastasize to 
bone, recent studies have focused on the question 
whether FGF8 has a role in bone metastasis. The first 
results show that FGF8 is involved in bone metastasis 
of prostate cancer (Valta et al., 2006; Valta et al.,
2008). 
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